Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration

  • Cabrera, Ingrid
  • Elizondo, Elisa
  • Rivera Gil, Pilar
  • Moreno, Evelyn
  • Faraudo, Jordi
  • Sala Vergés, Santiago
  • Bueno, María Dolores
  • González Mira, Elisabet
  • Ventosa, Nora
  • Veciana, Jaume
Lysosomal storage disorders (LSD) are caused by lysosomal dysfunction usually as a consequence of deficiency of a single enzyme required for the metabolism of macromolecules, such as lipids, glycoproteins, and mucopolysaccharides. For instance, the lack of α-galactosidase A (GLA) activity in Fabry disease patients causes the accumulation of glycosphingolipids in the vasculature leading to multiple organ pathology. Enzyme replacement therapy, which is the most common treatment of LSD, exhibits several drawbacks mainly related to the instability and low efficacy of the exogenously administered therapeutic enzyme. In this work, the unprecedented increased enzymatic activity and intracellular penetration achieved by the association of a human recombinant GLA to nanoliposomes functionalized with Arginine-Glycine-Aspartic acid (RGD) peptides is reported. Moreover, these new GLA loaded nanoliposomes lead to a higher efficacy in the reduction of the GLA substrate named globotriasylceramide in a cellular model of Fabry disease, than that achieved by the same concentration of the free enzyme. The preparation of these new liposomal formulations by DELOS-SUSP, based on the depressurization of a CO-expanded liquid organic solution, shows the great potential of this CO-based methodology for the one-step production of protein-nanoliposome conjugates as bioactive nanomaterials with therapeutic interest. α-galactosidase-A-(GLA)-loaded nano-liposomes functionalized with Arginine-Glycine-Aspartic acid (RGD) peptides are successfully prepared by using compressed CO. This nanoformulation shows an unprecedented increase of the GLA enzymatic activity and intracellular penetration, in comparison to the free enzyme. Moreover, these nanoconjugates lead to a higher efficacy in the reduction of the GLA substrate named globotriasylceramide (Gb3), in a cellular model of Fabry disease, than that achieved by the free enzyme., We acknowledge financial support from Instituto de Salud Carlos III, through “Acciones CIBER”. The Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) is an initiative funded by the VI National R&D&I Plan 2008-2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. The authors appreciate the financial support through the “Development of nanomedicines for enzymatic replacement therapy in Fabry disease” project, granted by the Fundació Marató TV3, BE-WELL (CTQ2013-40480-R) project granted by DGI (Spain), GenCat (2014-SGR-17) project financed by DGR (Catalunya), LIPOCELL project financed by CIBER-BBN and Praxis Pharmaceuticals, TERARMET (RTC-2014-2207-1) project financed by MEC (Spain) and excellence Grant CTS-6270 financed by “Junta de Andalucía>. The authors wish also to thank the Microscopy Service of UAB, especially Pablo Castro for the technical support in taking the Cryo-TEM images, and Mª Eugenia López Sánchez and Natalia García Aranda for their technical assistance in the in vitro activity assays. AV is recipient of an ICREA Academia (Generalitat de Catalunya) award. We acknowledge EMBL and Electra synchrotrons for beamtime allocation, and H. Amenitsch, B. Marmilori and B. Sartori for technical support at the SAXS beamline. Access to the synchrotron facility is supported by the BioStructX program (nº BIOSTRUCTX_1093). We also acknowledge computer time at the Minotauro-BSC supercomputer from the Red Española de Supercomputación (RES)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipid-based nanovesicles for nanomedicine

  • Grimaldi, Natascia
  • Andrade, Fernanda
  • Segovia Ramos, Nathaly V.
  • Ferrer Tasies, Lidia P.
  • Sala Vergés, Santiago
  • Veciana, Jaume
  • Ventosa, Nora
Molecular self-assembly has enabled the fabrication of biologically inspired, advanced nanostructures as lipid-based nanovesicles (L-NVs). The oldest L-NVs, liposomes, have been widely proposed as potential candidates for drug delivery, diagnostic and/or theranostic applications and some liposome-based drug products have already stepped from the lab-bench to the market. This success is attributed to their ability to encapsulate both hydrophobic and/or hydrophilic molecules, efficiently carry and protect them within the body and finally deliver them at the target site. These positive features are also coupled with high biocompatibility. However, liposomes still present some unsolved drawbacks, such as poor colloidal stability, short shelf-life, restricted and expensive conditions of preparation because of the inherent nature of their fundamental constituents (phospholipids). The new tools available in the self-assembly of controlled molecules have significantly advanced the field of L-NV design and synthesis, and nonliposomal L-NVs have been recently developed; this new generation of nanovesicles can represent a paradigm shift in nanomedicine: they may complement liposomes, showing their advantages and overcoming most of their drawbacks. Clearly, being still young, their rocky way to the clinic first and then to the market has just started and it is still long, but they have all the potentialities to reach their objective target. The purpose of this review is to first present the large plethora of L-NVs available, focusing on this new generation of non-liposomal L-NVs and showing their similarities and differences with respect to their ancestors (liposomes). Since the overspread of a nanomaterial to the market is also strongly dependent on the availability of technological-scale preparation methods, we will also extensively review the current approaches exploited for L-NV production. The most cutting-edge approaches based on compressed fluid (CF) technologies will be highlighted here since they show the potential to represent a game-change in the production of L-NVs, favouring their step from the bench to the market. Finally, we will briefly discuss L-NV applications in nanomedicine, looking also for their future perspectives., This work was financially supported by MINECO (DGI), Spain, grants BE-WELL CTQ2013-40480-R, TERARMET (RTC-2014-2207-1), QUATFORFRAG (RTC-2014-2183-5) and UNDERLIPIDS (RTC-2015-3303-1), and by AGAUR, Generalitat de Catalunya, “Grant 2014-SGR-17“. N.G. acknowledges the European Commission (EC) (FP7-PEOPLE-2013-Initial Training Networks (ITN) ‘‘NANO2FUN’’ Project No. 607721) for their Postdoctoral contract. The authors appreciate support from LIPOCELL project financed by CIBER-BBN and Praxis Pharmaceuticals and also acknowledge the financial support from Instituto de Salud Carlos III, through “Acciones CIBER”. The Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) is an initiative funded by the VI National R&D&I Plan 2008–2011, Iniciativa Ingenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pseudo-Wang Handle for the Preparation of Fully Protected Peptides. Synthesis of Liraglutide by Fragment Condensation

  • Carbajo, Daniel
  • Fransen, Peter Paul K.H.
  • El-Faham, Ayman
  • Royo, Miriam
  • Albericio, Fernando
A handle for the protection of the C-terminus of peptides after cleaving with low concentration of trifluoroacetic acid (2-4%) is reported. The handle prevents polymerization reactions in the convergent condensation of peptidic fragments. Moreover, it is traceless, being removed during the final deprotection step of the peptide synthesis. This cheap and convenient handle is easily attached to the solid support, causing no disturbance to peptide elongation and thus proving to be useful in the convergent synthesis of long peptides. © 2019 American Chemical Society., This work was funded in part by the following: Lonza AG (Wisp, Switzerland), the Spanish Ministry of Economy, Industry, and Competitiveness (MINECO) (CTQ2015-67870-P & RTC-2014-2207-1), CIBER-BBN, the Generalitat de Catalunya (2017 SGR 1439) (Spain), and the International Scientific Partnership Program ISPP at King Saud University (ISPP# 0061) (Saudi Arabia)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optimized Stepwise Synthesis of the API Liraglutide Using BAL Resin and Pseudoprolines

  • Carbajo, Daniel
  • El-Faham, Ayman
  • Royo, Miriam
  • Albericio, Fernando
The number of peptide-based active pharmaceutical ingredients (APIs) has increased enormously in recent years. Furthermore, the emerging new peptide drug candidates are more complex and larger. For the industrial solid-phase synthesis of C-carboxylic acid peptides, the two main resins available, Wang and chlorotrityl chloride (CTC), have a number of drawbacks. In this context, resins that form an amide bond with the first amino acid are more robust than Wang and CTC resins. Here, we address the use of the backbone (BAL) resin for the synthesis of the peptide liraglutide. The BAL resin, in conjunction with the use of pseudoprolines to avoid aggregation, allows the stepwise solid-phase synthesis of this API in excellent purity and yield. © 2019 American Chemical Society., Funding This work was funded in part by the following: Lonza AG (Visp, Switzerland), the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) (CTQ2015-67870-P and RTC-2014-2207-1), CIBER-BBN and the Generalitat de Catalunya (2017 SGR 1439) (Spain), and the International Scientific Partnership Program ISPP at King Saud University (ISPP# 0061) (Saudi Arabia). Notes The authors declare no competing financial interest., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New Bicistronic TALENs Greatly Improve Genome Editing

  • Martín-Fernández, Jose María
  • Fleischer, Aarne
  • Vallejo-Díez, Sara
  • Palomino, Esther
  • Sánchez-Gilabert, Almudena
  • Ruiz, Raúl
  • Bejarano, Yazmine
  • Llinás, Pere
  • Gayà, Antoni
  • Bachiller, Daniel
This article also appears in: Lineage Tracer and Gene-editing in Stem Cells., Genome editing has become one of the most powerful tools in present‐day stem cell and regenerative medicine research, but despite its rapid acceptance and widespread use, some elements of the technology still need improvement. In this unit, we present data regarding the use of a new, more efficient type of transcription activator‐like effector nuclease (TALEN) for gene editing. Our group has generated bicistronic genes in which classical TALEN coding sequences are linked by 2A elements to different reporter molecules, such as fluorochromes (TALEN‐F) or membrane receptors (TALEN‐M). This structure results in two proteins transcribed from the same transcript, of which the second (the reporter) can be used as the target for selection by fluorescence‐assisted cell sorting (FACS) or magnetic‐activated cell sorting (MACS). The application of these new TALEN genes allows a rapid enrichment of cells in which both members of the TALEN pair are active, thus eliminating the need for lengthy selection in culture and laborious characterization of a large number of clones. © 2020 by John Wiley & Sons, Inc., This work was supported by grants from the Spanish Ministry for Science and Innovation (PLE2009‐0091, RTC‐2014‐2207‐1 and IPT‐2011‐1402‐900000), ISCIII (PI14/01073 and PI18/00334), co‐funded by ERDF/ESF “Investing in your future”, the Balearic Government (16023/2008), the Spanish Cystic Fibrosis Federation (Pablo Motos grant), Federación ASEM‐Telemaratón “Todos somos raros, todos somos únicos”, Fundación Salud 2000, the European Commission (H2020, PHC‐667079), and an endowment from METROVACESA. J. M. M. F. was a postdoctoral Berrikertu fellow (granted by the Basque Government). A. F. was a recipient of Juan de la Cierva (JCI‐2006‐2675) and Torres Quevedo (PTQ‐16‐08496) postdoctoral fellowships from the Spanish Ministry for Science and Innovation.